Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2017

Open Access 01-12-2017 | Case Report

High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer

Authors: Shih-Wei Chen, Yen-Kung Chen

Published in: World Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers, and its value in the surveillance of post-operative colorectal cancer is well established. Fluorodeoxyglucose-positron emission tomography (FDG-PET) has been clinically used in colorectal cancer imaging including preoperative staging, evaluation of therapeutic response, detection of disease recurrence, and investigation of unexplained rising tumor markers.

Case presentation

We report a case of resected colorectal cancer presented with rising CEA levels in 5 years, and FDG-PET revealed no definitive evidence of recurrence except abnormal focal FDG uptake in the right thyroid lobe. However, fine needle aspiration cytology (FNAC) of the thyroid nodule showed negative for malignancy. Progressively rising CEA levels were noted over the following 5 years, but serial follow-up examinations did not find evidence of recurrence. Fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) was performed subsequently and again showed focal FDG uptake in the right thyroid lobe. This time, FNAC revealed positive for malignancy, in favor of medullary thyroid carcinoma (MTC). The patient underwent total thyroidectomy and modified radical neck dissection, and MTC with cervical nodal metastasis (pT3N1) was diagnosed. He had cervical lymph nodes recurrence 2 years later, which was resected.

Conclusions

This case reminded us that FDG-PET/CT may detect occult tumors resulting in CEA elevation other than colorectal cancer. Moreover, FNA has a higher false negative rate in detecting MTC than other forms of thyroid cancer. Repeat FNAC for the initial negative cytology result and measure of serum calcitonin for the early MTC detection could be more helpful to avoid the delay in MTC diagnosis.
Literature
1.
go back to reference Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park). 2006;20:579–87. Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park). 2006;20:579–87.
2.
go back to reference Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ. 2009;339:b3527.CrossRefPubMed Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ. 2009;339:b3527.CrossRefPubMed
3.
go back to reference Petersen RK, Hess S, Alavi A, Høilund-Carlsen PF. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. Am J Nucl Med Mol Imaging. 2014;4:471–82.PubMedPubMedCentral Petersen RK, Hess S, Alavi A, Høilund-Carlsen PF. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. Am J Nucl Med Mol Imaging. 2014;4:471–82.PubMedPubMedCentral
5.
go back to reference Sørensen CG, Karlsson WK, Pommergaard HC, et al. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence—a systematic review. Int J Surg. 2016;25:134–44.CrossRefPubMed Sørensen CG, Karlsson WK, Pommergaard HC, et al. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence—a systematic review. Int J Surg. 2016;25:134–44.CrossRefPubMed
6.
go back to reference Zervos EE, Badgwell BD, Burak WE Jr, et al. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery. 2001;130:636–43.CrossRefPubMed Zervos EE, Badgwell BD, Burak WE Jr, et al. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery. 2001;130:636–43.CrossRefPubMed
7.
go back to reference Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001;37:862–9.CrossRefPubMed Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001;37:862–9.CrossRefPubMed
8.
go back to reference Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319–23.CrossRefPubMedPubMedCentral Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319–23.CrossRefPubMedPubMedCentral
9.
go back to reference Marcus C, Whitworth PW, Surasi DS, et al. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol. 2014;202:1316–29.CrossRefPubMed Marcus C, Whitworth PW, Surasi DS, et al. PET/CT in the management of thyroid cancers. AJR Am J Roentgenol. 2014;202:1316–29.CrossRefPubMed
10.
go back to reference Chen YK, Ding HJ, Chen KT, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res. 2005;25:1421–6.PubMed Chen YK, Ding HJ, Chen KT, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res. 2005;25:1421–6.PubMed
11.
go back to reference Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Int Med. 1993;118:282–9.CrossRefPubMed Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Int Med. 1993;118:282–9.CrossRefPubMed
12.
go back to reference Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral
13.
go back to reference Hundahl SA, Fleming ID, Fremgen AM, Menck HRA. National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638–48.CrossRefPubMed Hundahl SA, Fleming ID, Fremgen AM, Menck HRA. National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638–48.CrossRefPubMed
14.
go back to reference Ganeshan D, Paulson E, Duran C, et al. Current update on medullary thyroid carcinoma. AJR Am J Roentgenol. 2013;201:W867–76.CrossRefPubMed Ganeshan D, Paulson E, Duran C, et al. Current update on medullary thyroid carcinoma. AJR Am J Roentgenol. 2013;201:W867–76.CrossRefPubMed
15.
go back to reference Simões-Pereira J, Bugalho MJ, Limbert E, Leite V. Retrospective analysis of 140 cases of medullary thyroid carcinoma followed-up in a single institution. Oncol Lett. 2016;11:3870–4.PubMedPubMedCentral Simões-Pereira J, Bugalho MJ, Limbert E, Leite V. Retrospective analysis of 140 cases of medullary thyroid carcinoma followed-up in a single institution. Oncol Lett. 2016;11:3870–4.PubMedPubMedCentral
16.
go back to reference van Veelen W, de Groot JW, Acton DS, et al. Medullary thyroid carcinoma and biomarkers: past, present and future. Intern Med. 2009;266(1):126–40.CrossRef van Veelen W, de Groot JW, Acton DS, et al. Medullary thyroid carcinoma and biomarkers: past, present and future. Intern Med. 2009;266(1):126–40.CrossRef
17.
go back to reference Ong SC, Schöder H, Patel SG, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48:501–7.CrossRefPubMed Ong SC, Schöder H, Patel SG, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48:501–7.CrossRefPubMed
Metadata
Title
High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer
Authors
Shih-Wei Chen
Yen-Kung Chen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-017-1303-4

Other articles of this Issue 1/2017

World Journal of Surgical Oncology 1/2017 Go to the issue